Chinese Journal of Dermatology ›› 2024, e20220795.doi: 10.35541/cjd.20220795
• Reviews • Previous Articles Next Articles
Ye Hui, Xue Rujun, Zhang Xibao
Received:
2022-11-10
Revised:
2023-06-08
Online:
2024-01-29
Published:
2024-05-08
Contact:
Zhang Xibao
E-mail:zxibao@126.com
Supported by:
Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis[J]. Chinese Journal of Dermatology,2024,e20220795. doi:10.35541/cjd.20220795
[1] | Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature[J]. Expert Opin Biol Ther, 2020,20(6):665⁃672. doi: 10.1080/14712598.2020.1727439. |
[2] | Al⁃Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review[J]. J Eur Acad Dermatol Venereol, 2020,34(7):1440⁃1448. doi: 10.1111/jdv.16246. |
[3] | Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti⁃tumour necrosis factor alpha: a cross⁃sectional study[J]. J Eur Acad Dermatol Venereol, 2008,22(12):1471⁃1477. doi: 10.1111/j.1468⁃3083.2008.02935.x. |
[4] | Napolitano M, Scalvenzi M, Fabbrocini G, et al. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series[J]. Dermatol Ther, 2019,32(6):e13142. doi: 10.1111/dth.13142. |
[5] | Jaulent L, Staumont⁃Sallé D, Tauber M, et al. De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort[J]. J Eur Acad Dermatol Venereol, 2021,35(4):e296⁃296e297. doi: 10.1111/jdv.17050. |
[6] | Flanagan KE, Pupo Wiss IM, Pathoulas JT, et al. Dupilumab⁃induced psoriasis in a patient with atopic dermatitis and alopecia totalis: a case report and literature review[J]. Dermatol Ther, 2022,35(2):e15255. doi: 10.1111/dth.15255. |
[7] | Tracey EH, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab[J]. JAAD Case Rep, 2018,4(7):708⁃710. doi: 10.1016/j.jdcr.2018.05.014. |
[8] | Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics[J]. J Allergy Clin Immunol, 2019,143(1):1⁃11. doi: 10.1016/j.jaci. 2018.10.032. |
[9] | Dai YX, Tai YH, Chang YT, et al. Bidirectional association between psoriasis and atopic dermatitis: a nationwide population⁃based cohort study[J]. Dermatology, 2021,237(4):521⁃527. doi: 10.1159/000514581. |
[10] | Chen WY, Chen SC, Hsu SY, et al. Annoying psoriasis and atopic dermatitis: a narrative review[J]. Int J Mol Sci, 2022,23(9):4898. doi: 10.3390/ijms23094898. |
[11] | Langan SM, Irvine AD, Weidinger S. Atopic dermatitis[J]. Lancet, 2020,396(10247):345⁃360. doi: 10.1016/S0140⁃6736(20)31286⁃1. |
[12] | Yang G, Seok JK, Kang HC, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis[J]. Int J Mol Sci, 2020,21(8):2867. doi: 10.3390/ijms21082867. |
[13] | Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes[J]. Int J Mol Sci, 2022,23(10):5518. doi: 10.3390/ijms23105518. |
[14] | Newsom M, Bashyam AM, Balogh EA, et al. New and emerging systemic treatments for atopic dermatitis[J]. Drugs, 2020,80(11):1041⁃1052. doi: 10.1007/s40265⁃020⁃01335⁃7. |
[15] | de Alcantara CC, Reiche E, Simão A. Cytokines in psoriasis[J]. Adv Clin Chem, 2021,100:171⁃204. doi: 10.1016/bs.acc.2020. 04.004. |
[16] | Safa G, Paumier V. Psoriasis induced by dupilumab therapy[J]. Clin Exp Dermatol, 2019,44(3):e49⁃e50. doi: 10.1111/ced. 13901. |
[17] | Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses[J]. J Exp Med, 2007,204(13):3183⁃3194. doi: 10.1084/jem.20071094. |
[18] | Al⁃Janabi A, Foulkes AC, Griffiths C, et al. Paradoxical eczema in patients with psoriasis receiving biologics: a case series[J]. Clin Exp Dermatol, 2022,47(6):1174⁃1178. doi: 10.1111/ced. 15130. |
[19] | Dumont⁃Berset M, Laffitte E, Gerber C, et al. Eczematous drug eruption after infliximab[J]. Br J Dermatol, 2004,151(6):1272⁃1273. doi: 10.1111/j.1365⁃2133.2004.06282.x. |
[20] | Senner S, Eicher L, Aszodi N, et al. Psoriasis in dupilumab⁃treated atopic dermatitis[J]. Hautarzt, 2020,71(5):383⁃386. doi: 10.1007/s00105⁃020⁃04565⁃8. |
[21] | Pouillot A, Dayan N, Polla AS, et al. The stratum corneum: a double paradox[J]. J Cosmet Dermatol, 2008,7(2):143⁃148. doi: 10.1111/j.1473⁃2165.2008.00379.x. |
[22] | Lee E, Min K, Ahn H, et al. Potential therapeutic skin microbiomes suppressing Staphylococcus aureus⁃derived immune responses and upregulating skin barrier function⁃related genes via the AhR signaling pathway[J]. Int J Mol Sci, 2022,23(17):9551. doi: 10.3390/ijms23179551. |
[23] | Munera⁃Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab[J]. J Eur Acad Dermatol Venereol, 2019,33(1):e40⁃e42. doi: 10.1111/jdv.15156. |
[24] | Kimura R, Sugita K, Yamamoto O. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab⁃induced eczema[J]. Eur J Dermatol, 2020,30(6):732⁃734. doi: 10.1684/ejd.2020.3904. |
[25] | Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature[J]. Expert Opin Biol Ther, 2020,20(6):665⁃672. doi: 10.1080/14712598.2020.1727439. |
[26] | Danset M, Hacard F, Jaulent C, et al. Brodalumab⁃associated generalized eczematous eruption in a difficult⁃to⁃treat psoriasis patient: management without brodalumab withdrawal[J]. Eur J Dermatol, 2020,30(6):741⁃743. doi: 10.1684/ejd.2020.3910. |
[27] | 李妍, 李明, 李邻峰. 湿疹样损害与银屑病样损害的免疫漂移[J]. 皮肤科学通报, 2023,40(1):37⁃43. |
[28] | Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases[J]. J Dermatol, 2018,45(6):732⁃734. doi: 10.1111/1346⁃8138. 14295. |
[29] | Nakajima K, Abe T, Saji R, et al. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy[J]. Allergol Int, 2020,64(4):382⁃383. doi: 10.1016/j.jinf. 2020.08.021. |
[30] | Hattori N, Koike Y, Murota H. Treatment with an interleukin⁃17 inhibitor resulted in complete remission of psoriasis and flare⁃up of atopic dermatitis[J]. J Dermatol, 2022,49(5):e173⁃e174. doi: 10.1111/1346⁃8138.16308. |
[31] | Burlando M, Cozzani E, Russo R, et al. Atopic⁃like dermatitis after secukinumab injection: a case report[J]. Dermatol Ther, 2019,32(1):e12751. doi: 10.1111/dth.12751. |
[32] | Koschitzky M, Tan K, Noliza Encarnacion MR, et al. Eczematous reactions to psoriasis biologics treated with dupilumab: a case series[J]. JAAD Case Rep, 2021,11:29⁃32. doi: 10.1016/j.jdcr. 2021.03.006. |
[33] | Mendes Roncada EV, Brambilla VR, Freitas Filitto B, et al. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis[J]. Case Rep Dermatol, 2021,13(2):336⁃339. doi: 10.1159/000513467. |
[34] | Paolino G, Di Nicola MR, Brianti P, et al. New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: the role of systemic treatments as a possible trigger[J]. Dermatol Ther, 2022,35(11):e15814. doi: 10.1111/dth.15814. |
[35] | Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report[J]. SAGE Open Med Case Rep, 2020,8:2050313X20904561. doi: 10.1177/2050313X20904561. |
[36] | Johnson MC, Bowers NL, Strowd LC. Concurrent atopic dermatitis and psoriasis vulgaris: implications for targeted biologic therapy[J]. Cutis, 2022,109(2):110⁃112. doi: 10.12788/cutis.0453. |
[37] | Fowler E, Silverberg JI, Fox JD, et al. Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis[J]. Dermatitis, 2019,30(3):234⁃236. doi: 10.1097/DER.0000 000000000481. |
[38] | Ferrucci S, Tavecchio S, Berti E, et al. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab[J]. Clin Exp Dermatol, 2020,45(5):625⁃626. doi: 10.1111/ced.14207. |
[39] | D′Ambra I, Babino G, Fulgione E, et al. Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns[J]. Dermatol Ther, 2020,33(6):e14169. doi: 10.1111/dth.14169. |
[40] | Parker JJ, Sugarman JL, Silverberg NB, et al. Psoriasiform dermatitis during dupilumab treatment for moderate⁃to⁃severe atopic dermatitis in children[J]. Pediatr Dermatol, 2021,38(6):1500⁃1505. doi: 10.1111/pde.14820. |
[41] | Maiolini VM, Sousa NA, Marsillac PF, et al. Alopecia areata⁃like and psoriasis after dupilumab use for atopic dermatitis[J]. An Bras Dermatol, 2021,96(5):634⁃636. doi: 10.1016/j.abd.2021. 03.005. |
[42] | Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report[J]. Br J Dermatol, 2021,185(2):432⁃434. doi: 10.1111/bjd.20064. |
[43] | Jia X, Li C, Wu J, et al. Pustular psoriasis aappearing induced by dupilumab therapy in a patient with atopic dermatitis[J]. J Drugs Dermatol, 2022,21(3):311⁃312. doi: 10.36849/JDD.6271. |
[44] | Zhong X, Li Y, Gao Y, et al. Pustular psoriasis appearing in a Chinese woman treated with dupilumab for atopic dermatitis: a case report[J]. Dermatol Ther, 2022,35(11):e15851. doi: 10. 1111/dth.15851. |
[45] | Fan J, Zhang L, Lu Y, et al. A case of dupilumab⁃induced reverse psoriasis in a patient with atopic dermatitis[J]. Dermatol Ther, 2022,35(4):e15345. doi: 10.1111/dth.15345. |
[1] | Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475. |
[2] | Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478. |
[3] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482. |
[4] | Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444. |
[5] | China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417. |
[6] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
[7] | Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378. |
[8] | Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429. |
[9] | Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865. |
[10] | Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394. |
[11] | Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448. |
[12] | Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230190-e20230190. |
[13] | Yao Wo, Wang Huiying. Lanadelumab in the treatment of hereditary angioedema: a systematic review of clinical trials [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230378-e20230378. |
[14] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
[15] | Wang Yukun, Liu Jie. Application of deep learning in non-neoplastic dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220660-e20220660. |
|